HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study)

Tangui Barré (1, 2) , Patrick Mercie (3) , Fabienne Marcellin (1) , Laure Esterle (3, 4, 5) , Claudine Duvivier (6, 7, 8, 9) , Elina Teicher (10, 11, 12) , Morgane Bureau (1) , Julie Chas (13) , Dominique Salmon-Ceron (14, 15) , Philippe Sogni (16, 17) , Maria Patrizia Carrieri (1) , Linda Wittkop (3, 17, 4, 5) , Camelia Protopopescu (1)

1 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
2 ORS PACA - Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille]
3 BPH - Bordeaux population health
4 INSERM U1219 - UB - ISPED - Team MORPH3EUS
5 CIC Bordeaux
6 Centre d'infectiologie Necker-Pasteur [CHU Necker]
7 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
8 IC UM3 (UMR 8104 / U1016) - Institut Cochin
9 CMIP - Centre Médical de l'Institut Pasteur
10 Hôpital Paul Brousse
11 DHU Hepatinov [Villejuif]
12 AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
13 CHU Tenon [AP-HP]
14 Service Maladies infectieuses et tropicales [AP-HP Hôpital Cochin]
15 UPD5 - Université Paris Descartes - Paris 5
16 Inserm U1223 - Physiopathologie du système immunitaire
17 Pôle de Santé publique [CHU Bordeaux]

In Western countries, tobacco smoking is highly prevalent among patients co-infected with HIV and hepatitis C virus (HCV). In the era of antiretrovirals and HCV cure, smoking-related health damages contribute greatly to morbidity and mortality in HIV-HCV co-infected patients. We used longitudinal data from the ANRS CO13 HEPAVIH cohort to identify the correlates of tobacco smoking quit attempts (TSQA) in HIV-HCV co-infected patients. TSQA were modelled using a multivariable discrete-time Cox proportional hazards model in 695 HIV-HCV co-infected tobacco smokers. HCV cure was associated with a 76% higher chance of TSQA (adjusted hazard ratio [95% confidence interval]: 1.76 [1.06-2.93], p = 0.029), and cannabis use with a 37% lower chance (0.63 [0.40-1.00], p = 0.049), independently of the mode of HIV transmission, other psychoactive substance use, and body mass index. Patients should be screened for tobacco and cannabis use at HCV treatment initiation and during follow-up. They should also be provided with comprehensive counselling and referral to addiction services. Non-smoking routes of cannabis administration should be promoted for cannabis users who wish to quit smoking tobacco.

Keywords: Cannabis; Tobacco; Smoking cessation; Human immunodeficiency virus; Hepatitis C; Chronic

Domains: Life Sciences [q-bio]; Santé publique et épidémiologie

Tangui Barré, Patrick Mercie, Fabienne Marcellin, Laure Esterle, Claudine Duvivier, et al.. HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). AIDS and Behavior, 2021, 25, pp.4141-4153. ⟨10.1007/s10461-021-03277-x⟩. ⟨hal-03268540⟩